Loading…
Loading…
HB Wealth Management LLC cut its position in Danaher Corporation (NYSE: DHR) by 13.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,772 shares of the conglomerate's stock after selling 7,499 shares during the period. HB Wealth Management LLC's
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
Ausdal Financial Partners Inc. purchased a new position in Danaher Corporation (NYSE: DHR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,452 shares of the conglomerate's stock, valued at approximately $467,000. Several other institutional investors and hedge funds have also
Bamco Inc. NY purchased a new stake in shares of Danaher Corporation (NYSE: DHR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 315,789 shares of the conglomerate's stock, valued at approximately $227,381,000. Several other hedge funds have also bought and sold shares
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Ally Financial Inc. purchased a new position in Danaher Corporation (NYSE: DHR) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 47,000 shares of the conglomerate's stock, valued at approximately $8,953,000. Danaher accounts for about 1.2% of Ally Financial Inc.'s
Callan Family Office LLC purchased a new position in Danaher Corporation (NYSE: DHR) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 4,198 shares of the conglomerate's stock, valued at approximately $3,023,000. A number of other large investors also recently modified their holdings of DHR. Keating